SRR8518299
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.330
- IL6_JAK_STAT3_SIGNALING+0.310
- MYOGENESIS+0.310
- UV_RESPONSE_DN+0.290
- COMPLEMENT+0.280
- COAGULATION+0.270
- KRAS_SIGNALING_UP+0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.240
- IL2_STAT5_SIGNALING+0.190
- INTERFERON_GAMMA_RESPONSE+0.180
Top 10 suppressed
- E2F_TARGETS-0.660
- MYC_TARGETS_V2-0.620
- MYC_TARGETS_V1-0.600
- G2M_CHECKPOINT-0.570
- MTORC1_SIGNALING-0.530
- OXIDATIVE_PHOSPHORYLATION-0.410
- PROTEIN_SECRETION-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.400
- DNA_REPAIR-0.390
- GLYCOLYSIS-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-L4-A4E6-01A-11R-A24H-07 | — | cohortA1 | 0.919 |
| 2 | 20040019.LumA | — | A | 0.916 |
| 3 | TCGA-S2-AA1A-01A-12R-A39D-07 | — | cohortA1 | 0.914 |
| 4 | TCGA-BH-A8G0-01A-11R-A352-07 | — | A | 0.912 |
| 5 | SRR8613742 | — | A | 0.906 |
| 6 | TCGA-99-AA5R-01A-11R-A39D-07 | — | cohortA1 | 0.905 |
| 7 | SRR26320092 | — | — | 0.904 |
| 8 | TCGA-98-A53C-01A-11R-A262-07 | — | cohortMD2 | 0.904 |
| 9 | DRR168582 | — | — | 0.904 |
| 10 | TCGA-55-8619-01A-11R-2403-07 | — | cohortA1 | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.330 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| HYPOXIA | 0.070 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.040 | Idelalisib | — uncovered |